Table 1. Patient characteristics (n = 118).
| Characteristics | No. | % |
|---|---|---|
| Age (years) | ||
| Median | 68 | |
| Range | 48–89 | |
| Gender | ||
| Male | 115 | 97.5 |
| Female | 3 | 2.5 |
| Subsite | ||
| Glottic | 84 | 71.2 |
| Supraglottic | 31 | 26.3 |
| Subglottic | 3 | 2.5 |
| cT stage | ||
| T1 | 16 | 13.6 |
| T2 | 57 | 48.3 |
| T3 | 31 | 26.3 |
| T4 | 14 | 11.9 |
| cN stage | ||
| N0 | 90 | 76.3 |
| N1 | 5 | 4.2 |
| N2 | 21 | 17.8 |
| N3 | 2 | 1.7 |
| TMN stage | ||
| I | 15 | 12.7 |
| II | 49 | 41.5 |
| III | 25 | 21.2 |
| IV | 29 | 24.6 |
| Treatment modality | ||
| Radiotherapy alone | 8 | 6.8 |
| CCRT | 110 | 93.2 |
| High dose regimen | (26) | (22.0) |
| Low dose regimen | (73) | (61.9) |
| Oral UFT | (11) | (9.3) |
| Treatment response | ||
| CR | 100 | 84.7 |
| non-CR | 18 | 15.3 |
| Recurrence after CR | 11 | 9.3 |
| Follow up duration, months | ||
| Median | 36 | |
| Range | 3–100 |
Abbreviations: CCRT = concurrent chemoradiotherapy; UFT = uracil-tegafur; CR = complete response.